Method of evaluating inflammatory skin disorders using IL-17...

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S085100, C424S085200, C424S184100, C435S004000, C435S006120, C514S04400A

Reexamination Certificate

active

07427402

ABSTRACT:
Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.

REFERENCES:
patent: 7090847 (2006-08-01), Oppmann et al.
patent: 7183057 (2007-02-01), Benson
patent: 2003/0083231 (2003-05-01), Ahlem et al.
patent: WO 99/60127 (1999-11-01), None
patent: WO 00/55204 (2000-09-01), None
patent: WO 01/46420 (2001-06-01), None
patent: WO 01/85790 (2001-11-01), None
patent: WO 02/078729 (2002-10-01), None
patent: WO 02/102411 (2002-12-01), None
patent: WO 2004/042009 (2004-05-01), None
patent: WO 2004/060291 (2004-07-01), None
patent: WO 2005/010044 (2005-02-01), None
Teunissen et al., J Invest Dermatol Oct. 1998; 111(4):645-649.
Kurasawa et al., Arth & Rheum Nov. 2000 43(11):2455-2463.
Romer et al., J Invest Derm Dec. 2003 121(6):1306-1311.
Griffiths et al., Br J Dermatol Jun. 1991; 124(6):519-26.
Aggarwal and Gurney (2002)J. Leukocyte Biology71:1-8 “IL-17: prototype member of an emerging cytokine family”.
Aggarwal et al. (2003)J. Biol. Chem. 278:1910-1914 Interleukin-23 Promotes a Distance CD4 T Cell Activation State Characterized by the Production of Interleukin-17.
Blumberg et al. (2001)Cell104:9-19 “Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function”.
Fossiez et al. (1996)J. Exp. Med. 183:2593-2603 “T Cell Interleukin-17 Induces Stromal Cells to Produce Proinflammatory and Hamatopoietic Cytokines”.
Ghoreschi et al. (2003)Nat Med9:40-46 “Interleukin-4 threapy of psoriasis Th2 responses and improves human autoimmune disease”.
Griffiths et al. (1991)Br J Dermatol. 124(6):519-526 “Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF-α) in allergic contact dermatitis (Rhus dermatitis)”.
Gudjonsson et al. (2004)Clin Exp Immunol. 135(1):1-8, Review “Immunopathogenic mechanisms in psoriasis”.
Kawaguchi et al. (2001)J. Immunol. 167:4430-4435 “Identification of a Novel Cytokine, ML-1, and Its Expression in Subjects with Asthma”.
Kawaguchi et al. (2004)J. Allergy Clin. Immunol. 114:1265-1273 “IL-17 cytokine family”.
Kennedy et al. (1996)J. Interferon Cytokine Res. 16:611-617 “Mouse IL-17: a cytokine preferntially expressed by alpha beta TCR+CD4-CD8-T cells”.
Kurasawa et al. (2000)Arth&Rheum. 43(11):2455-2463 “Increased Interleukin-17 Production in Patients with Systemic Sclerosis”.
Lee et al. (2004)J Exp Med199:125-130 “Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis vularis”.
Liao et al. (2002)J Immunol169:4288-4297 “IL-19 Induces Production of IL-6 and TNF-α”.
Liao et al. (2004)J Immunol. 173:6712-6718 “IL-19 Induced Th2 Cytokines and Was Up-Regulated in Asthma Patients”.
Nagalakshmi et al. (2004)Int Immunopharmacol4:577-592 “Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization”.
Oppmann et al. (2000)Immunity13:715-725 “Novel p19 Protein Engages Il-12p40 to From a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12”.
Parrish-Novak (2002),J Biol Chem277: 47517-47523 “Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes”.
Romer et al. (2003)J Invest Dermatol6:1306-1311 “Epidermal Overexpression of Interleukin-19 and -20 mRNA in Psoriatic Skin Disappears After Short-Term Treatment with Cyclosporine A or Calcipotriol”,
Rouvier et al. (1993)J. Immunol. 150:5445-5456 “CTLA-8, Clones from an Activated T Cell, Bearing AU-Rich Messenger RNA Instability Sequences, and Homologous to a Herpesvirus Saimiri Gene”.
Starnes et al. (2001)J. Immunol. 167:4137-4140 “Cutting Edge: IL-17F, a Novel Cytokine Slectively Expressed in Activated T Cells and Monocytes, Regulates Angiogenesis and Endothelial Cell Cytokine Production”.
Teunissen et al. (1998)J. Invest. Derm. 111(4):645-649. Review “Interleukin0-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes”.
Witowski et al. (2004)Cellular and Molecular Life Sciences61(5):567-579 “Interleukin-17: a mediator of inflammatory respones”.
Wang et al. (2002)J. Biol Chem277:7341-7347 “Interleukin 24 (MDA-7/MOB-5) Signals through Two Heterodimeric Receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2”.
Wiekowski et al. (2001)J. Immunol. 166:7563-7570 “Ubiquitous Transgenic Expression of the Il-23 Subunit p19 Induces Multiorgan Inflammation, Runting, Infertility, and Premature Death”.
Yao et al. (1995)Immunity3:811-821 “Herpesvirus Saimiri Encodes a New Cytokine, IL-17, Which Binds to a Novel Cytokine Receptor”.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method of evaluating inflammatory skin disorders using IL-17... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of evaluating inflammatory skin disorders using IL-17..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of evaluating inflammatory skin disorders using IL-17... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3967283

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.